AgingResearch.NewsJoin free

Glucosylceramide synthase inhibitors

Intervention

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab
  • Funder: Curtin University of Technology
  • 3 of 3 findings with company ties
  • Animals1

Outcomes

3

Glucosylceramide

downin mice1

1 study

  1. Glucosylceramide synthase inhibitors decrease glucosylceramide in mice.

    “reduce substrates in this animal model while significantly enhancing its lifespan”

    Animalsin a mouse model of neuropathic Gaucher diseasebrain

    Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease

    PloS one17 Aug 2012

More on Glucosylceramide

CNS pathology

downin mice1

1 study

  1. Glucosylceramide synthase inhibitors decrease CNS pathology in mice.

    “reduction of substrate accumulation and CNS pathology together with a significant increase in lifespan after systemic administration of a novel glucosylceramide synthase inhibitor”

    Animalsin a mouse model of neuropathic Gaucher diseaseCNS

    Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease

    PloS one17 Aug 2012

Lifespan

upin mice1

1 study

  1. Glucosylceramide synthase inhibitors extend lifespan in mice.

    “significant increase in lifespan after systemic administration of a novel glucosylceramide synthase inhibitor to a mouse model of nGD”

    Animalsin a mouse model of neuropathic Gaucher disease

    Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease

    PloS one17 Aug 2012

Latest

Related